It's all by design
It's all by design
It's all by design
SCILEX is more than just a pharmaceutical company. It’s a team of passionate and dedicated people who have faith in forward-thinking technologies and who believe that helping patients better manage their pain can lead toward a better quality of life. Learn more about the people who make up what we think is a pretty amazing place.

Leadership by design

Legal, Finance, Clinical, Regulatory, and Product Commercialization

The mission of the Leadership Team is to bolster our proprietary pain management technology by employing years of expertise that comes with overseeing market access, commercialization, advocacy, and government affairs programs. These seasoned professionals bring SCILEX a type of leadership that is unmatched in the pharmaceutical industry.


Henry Ji, Ph.D

Executive Chairman

25+ years of experience in the biotechnology and life sciences industry

Dr. Ji co-founded Sorrento and has served as a director since 2006, CEO and President since 2012, and Chairman
since 2017

During his tenure at Sorrento, he has engineered and led a phenomenal growth of Sorrento through acquisition and merger including Bioserv, Scilex Pharmaceuticals, Concortis Biotherapeutics, Levena Biopharma, LACEL, TNK Therapeutics, Virttu Biologics, Ark Animal Health, and Sofusa Lymphatic Delivery Systems

Served as Sorrento’s Chief Scientific Officer from 2008 to 2012 and as its Interim CEO from 2011 to 2012

Prior to Sorrento, he held senior executive positions at CombiMatrix, Strategen and also co-founded Stratagene Genomics, a subsidiary of Stratagene, and served as its President & CEO and Director of the Board

B.S. and Ph.D.

Jaisim Shah

Chief Executive Officer & President

Jaisim Shah is a successful life science leader with significant success in global business development and product commercialization. Jaisim’s track record of success in leading teams in the commercialization of some of today’s most recognized pharmaceutical brands. Innovation, collaboration and patient care has been at the heart and soul of his extensive life science career and they are guiding principles for Scilex/Semnur. Jaisim has been CEO and President of Semnur Pharmaceuticals (acquired by Scilex Pharmaceuticals) since its inception in 2013. Jaisim also serves as CEO and President of Scilex Holding and Scilex Pharmaceuticals since March 2019 and on the Board of Directors for Sorrento Therapeutics Inc. Most recently, Jaisim served as Chief Business Officer of Elevation Pharmaceuticals where he focused on financing, mergers and acquisitions, and business development. He led the sale of Elevation to Sunovion Dainippon Sumitomo Pharmaceuticals in 2012. Formerly, he was the chief business officer and senior vice president of business development at CytRx, a biopharmaceutical company which specializes in oncology. At Facet Biotech and PDL BioPharma, he served from 2000 to 2009 as chief business officer and also held the position of senior vice president of marketing and medical affairs. Here he completed numerous licensing/ partnering and strategic transactions including with Roche, Bristol-Myers Squibb, Otsuka and Biogen Idec. His leadership in marketing and leading the commercial enterprise helped the company make large improvements to meet its profitability potential. At Bristol-Myers Squibb, as vice president of global marketing from 1997 to 2000 he received the “Presidents Award” for completing one of the most significant collaborations in the company’s history. Prior to working with Bristol-Myers Squibb, Mr. Shah led international marketing for oncology and virology and was global business leader for corporate alliances at Roche from 1991 to 1997 with Genentech and Idec, and prepared products for worldwide launch and pre-launch at F. Hoffman-LaRoche AG in Switzerland. He has played a key role in the formulation of long-range plans and pre-launch and launch strategies for such brands as Abilify®, Pegasys® and Rituxan/MabThera®, each of which have generated well over $1 billion in sales. Jaisim holds an MA in Economics from the University of Akron and an MBA from University of Oklahoma.

Suketu D. Desai, Ph.D.

Chief Technical Officer & Senior Vice President, Chemistry, Manufacturing & Controls, Regulatory CMC & Quality

Suketu D. Desai, Ph.D. has 25+ years of experience in the Biologics and Pharmaceutical Industry. Suketu is Chief Technical Officer and Senior Vice President, Chemistry, Manufacturing and Controls, Regulatory CMC and Quality at Semnur Pharmaceuticals (acquired by Scilex Pharmaceuticals), Inc., (2015-current). Prior to Semnur, Suketu was Vice President of Biologics Development and Manufacturing for biologics drug substance and drug product, technical due diligence and commercial technical operations at Allergan, Inc. (2014-2015), which was acquired by Actavis, plc. Before Allergan, Suketu was a CMC consultant in 2013. Suketu was Vice President, Biotechnology Technical Operations for biologics drug substance and drug product, analytical, manufacturing and technical due diligence at Cephalon, Inc. (2010-2012), which was acquired by Teva Pharmaceuticals. During 2007-2010, Suketu was Ception Therapeutics, Inc., Vice President, Chemistry, Manufacturing and Controls (CMC) and Quality responsible for biologics drug substance and drug product development, analytical, manufacturing, quality, regulatory CMC and technical due diligence for business development. Ception was acquired by Cephalon (2010).

Earlier, Suketu was Principal Scientist, Process Sciences/Technical Operations for late-stage and commercial biologics drug substance and drug product at Centocor, Inc., a Johnson & Johnson subsidiary (2003-2006); Assoc. Director, Pharmaceutical and Biologic Formulations Development at AAI Pharma Development Services (2001-2003); Director/Sr. Manager at Aronex Pharmaceuticals, Inc. (1996-2001); and Senior Scientist II/I at Novartis Pharmaceuticals, formerly Alcon Labs, Inc., (1992-1996).

Suketu has contributed to several commercial biologic products (Botox, Cinquair, Simponi, Remicade, ReoPro, Retavase, Eprex) and pharmaceutical products (Azopt and Volfenol) and late-stage products including SP-102 and abicipar pegol.

Suketu has experience in biologics development, pharmaceutical development, internal and contract manufacturing, process validation, methods development and validation, quality, CMC regulatory and pre-approval inspection, clinical and commercial supply chain, CMC outsourcing, contract manufacturing organization (CMO) management and technical due diligence. He has managed CMOs in US, Europe and Asia for biologics and pharmaceutical drug substance and drug products.

Dr. Desai received his Ph.D. in Pharmaceutical Sciences from the University of Arizona, Tucson, AZ and Master’s in Pharmacology and Bachelor’s in Pharmacy from the University of Mumbai, Mumbai, India.

Dmitri Lissin, M.D.

Chief Medical Officer and Senior Vice President, Clinical Development and Medical Affairs

Dmitri Lissin currently serves as Chief Medical Officer and Senior Vice President, Clinical Development and Medical Affairs of Scilex/Semnur Pharmaceuticals. Prior to Semnur, from 2011-2015, Dmitri was Vice President of Clinical Development at Xenoport, responsible for conduct of multiple clinical research programs in neurology and dermatology. From 2006-2011 Dmitri directed a clinical research team and served as member of the Executive Committee at DURECT Corporation, designing and executing clinical trials in chronic nociceptive, neuropathic, and acute post-operative pain, which led to successful licensing deals and NDA filings. From 1998-2006 Dmitri managed various clinical R&D programs at Titan Pharmaceuticals, Aerogen and Synarc. Dr. Lissin has a broad expertise with proprietary drug-delivery technologies applied to therapeutic products spanning numerous clinical areas, including pain and neurological disorders. Most of his experience involves clinical development of novel oral, transdermal, implantable and injectable formulations containing existing active pharmaceutical ingredients, using 505(b)(2) drug approval pathway. He has participated in many Pre-IND, End of Phase 1, End of Phase 2 and Pre-NDA meetings, negotiating clinical development programs with the FDA Division of Anesthesia, Analgesia, and Addiction Products (DAAAP), Division of Neurology Products and Division of Dermatology and Dental Products. He received his post-doctoral training at the University of California San Francisco, and his medical degree through an exchange program between Russian National Medical University and Harvard Medical School.

Suresh Khemani

Senior Vice President, Commercial Operations, Sales, Market Access and Marketing

Suresh Khemani has 25+ years of senior management experience in the industry and successfully launched both specialty and large market products. His therapeutic areas include pain, neurology, oncology, immunology and CV. Suresh is a board member of Full Spectrum Genetics, an antibody technology company.

Najjam Asghar

Interim Chief Financial Officer

Najjam serves as Chief Financial Officer (CFO) leading the functions of Finance, Accounting and Tax and has over 17 years of experience. Prior to joining Scilex, he worked at NuVasive, Inc. leading various accounting and finance functions. He was instrumental in several acquisitions to build upon NuVasive’s portfolio of products, segments, geographic expansion and helped the Company achieve its goal of more than $1 billion revenue. He started his career with PricewaterhouseCoopers, where he served various S&P 100 and S&P 500 clients in North America and Asia in the audit and assurance practice Najjam hold a Bachelor of Arts degree.

Steve Lincoln

interim General Counsel, Chief Compliance Officer

Steve Lincoln serves as interim General Counsel, Chief Compliance Officer for Scilex Holding Company and Scilex Pharmaceuticals. Steve has been involved in the biopharma industry for more than 18 years. Most recently, he has been Of Counsel to the law firm of Brown Gee & Wenger, where his corporate practice has included several publicly traded and private biopharma companies. Before that, Steve served in in-house counsel roles at SciClone Pharmaceuticals (acquired by GL Capital), Kosan Biosciences (acquired by Bristol Myers Squibb), SuperGen (now Astex Pharmaceuticals, a subsidiary of Otsuka), and Protein Design Labs (later Facet Biotech, acquired by AbbVie). Steve is a graduate of Brown University and the Boston University School of Law.

Principled by design

We are committed to following these tenets of good business that have
helped shape the Mission, Vision, and Values by which we run SCILEX.


SCILEX Pharmaceuticals responsibly develops and brings branded products to market using technologies designed to maximize the quality of life for patients we serve.


We are uncompromising in our focus to become the global pharmaceutical leader in pain management through social, environmental, economic and ethical principles.








Integrity by design
Integrity by design
Integrity by design

Integrity by design

The ethical standards that govern how SCILEX conducts business reflect the company's commitment to integrity and excellence. The following documents outline the guiding principles and the internal structures we have in place to monitor them.

Governance Documents

California Compliance

It's all by design
It's all by design
It's all by design

Not your typical pharma

We’re not just your average pharmaceutical company. We’re a different breed altogether. Ours is a passionate team of talented people working together to make a difference in the world of pain management. Our team-spirited approach ensures a collaborative, engaged, and focused atmosphere where we push thinking further, fostering innovation and fervently pursuing viable solutions for patients and providers through groundbreaking technologies. We believe in the “law of science” and that we’re all entitled to live healthy and pain-free lives—because we’re patients, too. We don’t just seek answers. We seek THE answer.


Share This Page